Parliament Workbench
Data: Motions & questions to 19 Nov 2026

Written Question · S2W-20685 · Session 2

How many NHS boards have made bortezomib (Velcade) available to patients who have requested such treatment.

Answered Asked by Margaret Ewing SNP Lodged 15 Nov 2005

The question

To ask the Scottish Executive how many NHS boards have made bortezomib (Velcade) available to patients who have requested such treatment.

The answer

Answered by Andy Kerr on 23 Nov 2005 · 8 days after it was lodged, on time

Information on drug treatments given in hospitals is not available centrally. Data collected centrally relate to prescribed items dispensed by community pharmacists and dispensing doctors. These data are not patient-specific.
The Scottish Medicines Consortium has recommended that bortezomib is accepted for use within NHS Scotland for the treatment of patients with multiple myeloma who have already received at least two therapies, have seen their disease progress on the last therapy and who are unresponsive to alternative licensed treatments for this stage of the disease.
NHS boards should therefore ensure that bortezomib is made available according to clinical need.

In the Official Report

No contribution in the Official Report cites S2W-20685 by reference.